The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.
As such, there can be a revolving door of healthcare names for investors to watch, and the most talked-about companies are often ones with pending trial data or other major developments on the horizon.
